Oak Hill Bio and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of bronchopulmonary dysplasia in premature infants. Additional Oak Hill Bio assets that have ...

Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...

Longevity science has spent decades chasing single molecules that might slow aging, but most candidates have delivered modest ...

Obesity and diabetes treatment is undergoing a revolution with the advent of GLP-1 drugs, which help manage weight, control ...

Gandhinagar: A recent NITI Aayog report on the globalisation of higher education has praised the Gujarat government's ...

According to health and wellness group, David Lloyd Clubs, 'bio-syncing' your workout routine is going to be a top trend in ...

"What we want to know is what is the pain that you are solving for your customers and who is willing to pay for your solution ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but the strategy behind the ...

In 2025, artificial intelligence moved from pilot projects to practical use across the U.S. military. From Army intel and ...

Share Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock ...

Learn the official portal workflow, Aadhaar/PAN verification, NIC code selection, and certificate generation to complete MSME registration efficiently and avoid common ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...